Fig. 9

Prediction of treatment response by the NRSHC. (A) Differences in expression levels of immune checkpoint genes between different risk groups. (B–C) TMB analysis of HCC patients in high-risk and low-risk groups. (D) Difference in IPS between the two groups. (E) Differences in IC50 values of chemotherapy drugs between the two risk groups.